News Quantified

ASLN – aslan pharmaceuticals limited - american depositary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics [Yahoo! Finance]

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab [Yahoo! Finance]

Form 6-K ASLAN Pharmaceuticals For: May 07

Form 6-K ASLAN Pharmaceuticals For: Apr 22

Form 6-K ASLAN Pharmaceuticals For: Apr 19

Form 424B5 ASLAN Pharmaceuticals

Form 6-K ASLAN Pharmaceuticals For: Apr 12

Top News Gainers

11/22 ASLAN Pharmaceuticals Announces Publication of Preclinical Data on ASLAN003 in AML in Haematologica Journal 293.2%

12/2 ASLAN Pharmaceuticals Reports Positive Preliminary Data From Proof-of-Concept Study for ASLAN004 Targeting Atopic Dermatitis 30.0%

4/13 ASLAN Intends to Resume Screening as Soon as Government Restrictions are Lifted and is Taking Steps to Open Sites in Australia to Accelerate Recruitment 28.2%

3/24 ASLAN PHARMACEU/ADR (NASDAQ: ASLN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.00 price target on the stock. 25.3%

10/31 ASLAN Pharma files to offer $100M in shares [Seeking Alpha] 20.7%

7/31 ASLAN Pharmaceuticals to Present New Data on Varlitinib at European Society for Medical Oncology Congress 9.6%

8/15 ASLAN PHARMACEU/ADR (NASDAQ: ASLN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. 8.7%

11/14 ASLAN PHARMACEU/ADR (NASDAQ: ASLN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock, down previously from $9.00. 7.8%

9/10 Abstract on ASLAN Pharmaceuticals’ Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019 7.0%

5/27 ASLAN PHARMACEU/ADR (NASDAQ: ASLN) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.6%

Top News Decliners

11/11 ASLAN Pharmaceuticals Announces Topline Results From TreeTopp Global Pivotal Study of Varlitinib in Biliary Tract Cancer -67.8%

12/3 ASLAN Pharmaceuticals Announces Pricing of $12.8 Million Public Offering of American Depositary Shares -54.0%

12/2 ASLAN PHARMACEU/ADR (NASDAQ: ASLN) was upgraded by analysts at Piper Jaffray Companies from a "neutral" rating to an "overweight" rating. -26.4%

11/29 Aslan Pharmaceuticals bid up again [Seeking Alpha] -26.4%

11/12 Form 6-K ASLAN Pharmaceuticals For: Nov 11 -26.1%

4/16 Form 20-F ASLAN Pharmaceuticals For: Dec 31 -19.0%

3/18 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update -10.5%

5/31 Titagarh Wagons Approved Amalgamation Of 3 Units With Co [Reuters] -10.2%

8/26 Great Bay Bio's 3D Advisory Board Science Committee Welcomes Another New Arrival -8.5%

12/4 Form 424B5 ASLAN Pharmaceuticals -8.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day